Jim Glasheen, PhD
Jim Glasheen, PhD, is the executive vice chancellor for innovation and business development at UMass Medical School, a position in which he leads a comprehensive and strategic approach to strengthening the scope and impact of the medical school’s biomedical research enterprise, which currently exceeds $250 million in annual external funding; and leveraging the commercialization of the IP portfolio through alliances, collaborations, agreements and partnerships with new and established life sciences partners.
Dr. Glasheen was previously a general partner at Technology Partners, a venture capital fund in California. Companies in which he was an investor and/or board member include Cadence Pharmaceuticals (CADX then acquired by Mallinckrodt), Revance Therapeutics (RVNC), Iomai (IOMI then acquired by Intercell), Incline Therapeutics (acquired by The Medicines Company), Transcend Medical (acquired by Novartis), Vision 5 (acquired by Allergan), Corcept (CORT), and Elcelyx (private).
Glasheen is also the co-founder and co-chairman of the ConsumerMed, a nonprofit organization focused on patient-centered health. Prior to his venture career, he was a consultant with McKinsey and Company and was a leader within their pharmaceuticals and medical products practice.
He is a graduate of Duke University and Harvard University, where he earned a PhD in biology. He completed by a postdoctoral fellowship at the University of California Berkeley.